BriaCell Therapeutics Corp.
BCTX evidence brief
What we can confirm
- Market Cap:
- $31.6M
What it means
What to watch
Prepared research question
What matters most for BCTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BCTX
BriaCell Therapeutics Corp. (BCTX) is a clinical-stage biotechnology company developing novel immunotherapies for cancer, with a lead Phase 3 trial in metastatic breast cancer and next-generation personalized platforms in preclinical/early-stage development.
Key risk: Cash runway limited
Market Cap
$31.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Apr 30, 2026.
Tracking 2 clinical trials for BriaCell Therapeutics Corp..
BriaCell Therapeutics Corp. (BCTX) is a clinical-stage biotechnology company developing novel immunotherapies for cancer, with a lead Phase 3 trial in metastatic breast cancer and next-generation personalized platforms in preclinical/early-stage development.
- Lead program Bria-IMT is in a pivotal Phase 3 study for metastatic breast cancer, with top-line data anticipated as early as H1-2026 [news · 2025-12-18].
- Final Phase 2 data for Bria-IMT showed median overall survival of 16.6 months (with Phase 3 formulation) [news · 2026-05-22].
- Next-generation platform Bria-OTS+ demonstrated potent, durable activation of innate and adaptive immunity in preclinical models [news · 2026-04-21].
- BriaCell completed manufacturing of clinical supplies for Bria-PROS+, a personalized immunotherapy for prostate cancer, and plans to initiate a Phase 1/2a study [news · 2026-05-14].
- Cash & equivalents were $6.9M as of 2026-04-30, with a net loss of -$7.2M for the period [sec].
What works
- Bria-IMT Phase 3 trial was featured in Nature Medicine as one of 'Eleven clinical trials that will shape medicine in 2026,' indicating high scientific interest [news · 2026-09-08].
- Positive quality-of-life data and biomarker predictors of response from the ongoing Phase 3 study support the therapeutic rationale [news · 2026-05-22].
- The company is expanding its pipeline with Bria-OTS+ and Bria-PROS+, targeting multiple cancer types beyond breast cancer [news · 2026-05-14].
What to weigh
- The company reported a net loss of -$7.2M as of 2026-04-30, with cash of only $6.9M, suggesting a limited runway without additional financing [sec].
- Bria-IMT is still in Phase 3; regulatory approval and commercial success are not guaranteed and depend on final data [news · 2026-09-08].
- Next-generation platforms (Bria-OTS+, Bria-PROS+) are at preclinical or early clinical stages, with no proof-of-concept in humans yet [news · 2026-04-21].
From the filings
Quoted directly from source documents.
Phase 3 trial enrollment at MSK and Nature Medicine recognition
“Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as “Eleven clinical trials that will shape medicine in 2026””
News · September 8, 2026
Final Phase 2 median overall survival of 16.6 months
“Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation)”
News · May 22, 2026
Bria-OTS+ preclinical activity
“Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line models”
News · April 21, 2026
Catalyst timeline
- 2023-12-05 · Phase 3 Start — Randomized, open-label study of Bria-IMT regimen plus checkpoint inhibitor vs physician's choice in advanced metastatic breast cancer.
Risks & what to watch (3)›
Key risks
- Cash runway limited — Cash of $6.9M as of 2026-04-30 may not sustain operations through Phase 3 completion without additional funding [sec].
- Phase 3 data uncertainty — Top-line data from the pivotal Phase 3 trial is not yet reported; efficacy or safety may fall short [news · 2025-12-18].
- Early-stage pipeline risk — Next-gen platforms (Bria-OTS+, Bria-PROS+) are preclinical or early clinical; no human data yet [news · 2026-04-21].
What to watch
- Top-line Phase 3 data for Bria-IMT, anticipated as early as H1-2026 [news · 2025-12-18].
- Initiation of Phase 1/2a study for Bria-PROS+ in prostate cancer [news · 2026-05-14].
- Further biomarker and survival data presentations at upcoming conferences (e.g., ASCO, SABCS) [news · 2026-04-27].
- Cash position and any financing or partnership announcements given limited runway [sec].
Sources: Catalysts · News · Generated October 13, 2026 · How we verify sources →
Run BriaCell Therapeutics Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BriaCell Therapeutics Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$1.6M
| Holder | Shares | Value |
|---|---|---|
| cable car capital, lp | 216,821 | $908K |
| sabby management, llc | 73,915 | $310K |
| iridian asset management llc/ct | 65,000 | $272K |
| luminarx capital management lp | 15,000 | $63K |
| ubs group ag | 11,541 | $48K |
| morgan stanley | 3,021 | $13K |
| national bank of canada /fi/ | 802 | $3K |
| federation des caisses desjardins du quebec | 455 | $2K |
| allworth financial lp | 100 | $419 |
| td waterhouse canada inc. | 19 | $78 |
Showing top 10 of 16 institutional holders of BriaCell Therapeutics Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 6.5%
- Days to cover
- 3.1
- Shares short
- 472,347
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BCTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for BriaCell Therapeutics Corp.?
BriaCell Therapeutics Corp. (BCTX) is a clinical-stage biotechnology company developing novel immunotherapies for cancer, with a lead Phase 3 trial in metastatic breast cancer and next-generation personalized platforms in preclinical/early-stage development.
Who is the CEO of BriaCell Therapeutics Corp.?
Dr. William V. Williams FCPA, M.D. is the chief executive officer of BriaCell Therapeutics Corp. (BCTX).
Where is BriaCell Therapeutics Corp. headquartered?
BriaCell Therapeutics Corp. (BCTX) is headquartered in West Vancouver, BC, Canada.
What therapeutic areas does BriaCell Therapeutics Corp. focus on?
BriaCell Therapeutics Corp. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.